Skip to main content
. Author manuscript; available in PMC: 2010 Aug 27.
Published in final edited form as: Vaccine. 2009 Jul 8;27(39):5402–5410. doi: 10.1016/j.vaccine.2009.06.063

Figure 3.

Figure 3

Cost-effectiveness analysis of HIV vaccination over 20 years

(a) Cost-effectiveness of universal, high-risk group targeted, or low-risk group targeted vaccination. Assumes a vaccine with 75% efficacy, lifetime duration of protection, and $1000 price, and 75% coverage of the target population.

(b) Cost-effectiveness of universal vaccination under different vaccine efficacy (25%, 50%, 75%, 100%) and duration of protection (5-year, 10-year, lifetime) scenarios. Assumes a vaccine with $1000 price, and 75% coverage of the target population. Incremental cost-effectiveness ratios are relative to the status quo (no vaccination).